1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Vinpai S.A.

Vinpai S.A.

EEURONEXT:ALVIN
2.66
EUR
+0.24
(+9.92%)
10.23MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.31
1.53
1.85
2.37
2.67
2.25
- -
Basic EPS, GAAP
- -
-0.48
-0.44
-1.03
-0.85
-1.07
- -
Free Cash Flow per Basic Share
- -
- -
-0.1
-0.93
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.76
0.32
0.13
0.66
-0.13
-0.51
-0.13
Tangible Book Value per Share
-0.04
-0.55
-0.84
-0.35
-1.16
-1.28
-1.16
Basic Weighted Avg Shares
3
3
3
3
3
5
3
Sales/Revenue/Turnover
4
5
6
8
9
10
- -
Operating Margin (%)
-12.57
-31
-20.27
-21.98
-27.31
-46.36
- -
Depreciation Expense
- -
- -
1
1
- -
3
- -
Net Income, GAAP
- -
-2
-1
-3
-3
-5
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
0.09
-31.33
-23.91
-43.45
-31.87
-47.59
- -
Working Capital
2
2
2
2
2
-1
2
LT Debt
3
5
6
5
7
5
7
Total Equity
3
1
- -
2
- -
-2
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-88.45
-194.89
-260.18
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
- -
2
- -
LT Borrowings
5
5
7
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
18
13
10

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
4
5
4
Cash, Cash Equivalents & STI
- -
- -
1
Accounts Receivable, Net
1
1
1
Inventories
2
2
1
Total Current Liabilities
2
4
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
2
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
116.58%
414.06%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
-7,746.28%
66.49%
Sales/Revenue/Turnover
- -
18.51%
11.51%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
8
2024
- -
- -
9
2025
- -
- -
10

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.03
2024
- -
- -
-0.85
2025
- -
- -
-1.07

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Philippe Le Ray
Full Time Employees
39
Sector
Health technology
Industry
Pharmaceuticals: other
Address
6 PA de la Fouée Saint-Dolay BRE France 56130
IPO Date
Jul 19, 2023
Website
vinpai.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Vinpai SAS (ALVIN.PA) designs, manufactures and markets functional ingredients based on algae, plants, minerals and fibers as natural alternatives to chemical additives for the food, cosmetics, nutraceuticals and medical devices industries; its core offerings include plant-based flavors, premixes for analogue cheeses, dairy products, dressing sauces, French fries, cakes and sweetness products; technical and algae-origin solutions such as salt reduction, filling, meat applications and algal texturing for food; algaromatherapy, algatherapy ingredients, ocean sulfated polysaccharides, essential trace elements, amino acids, biomic fibers and unsaturated fatty acids for food supplementation; algae-mineral peel-off masks, actives and ingredients solutions for cosmetics; and algae-origin medical devices including algin patches, molding powders, aesthetic and dental hygiene products. Founded in 2011 and headquartered in Saint-Dolay, France, with production sites in Saint-Dolay and near Saint-Nazaire, the company operates two facilities, employs around 43-47 people and serves customers in over 36 countries with more than 70% of its €9.2 million 2024 revenue generated from exports, primarily in the food sector (83% of sales). Recent developments include a May 2024 strategic partnership with Enhance Gourmet Foods in India to supply plant-based ingredients for vegan cheeses and expand in Asia, the launch of Vin'Curd+ in Q2 2024 for cheese coagulation productivity and ULTRATEX CARE for cold-process cosmetic emulsions, a February 2025 memorandum of understanding with Camlin Fine Sciences Ltd. for a majority stake acquisition supported by €3.3 million in convertible bonds to repay debt and bolster cash, and confirmation of 2026 targets for €16 million revenue and over 10% EBITDA margin amid ongoing industrial scaling and international growth.